CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 337 enrolled
Drug / intervention
Tezepelumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04039113
NCT04039113Phase 2Completed
CompareCT.gov

A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) (COURSE)

AstraZeneca·interventional·Posted Jul 31, 2019·Updated Feb 18, 2025

In Brief

A Phase 2 clinical trial evaluating Tezepelumab and Placebo for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 337 participants across 91 sites in 10 countries.

Detailed Summary

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease (COPD)
CountriesCanada, Denmark, France, Germany, Israel, Netherlands, South Korea, Spain, United Kingdom, United States
CollaboratorsAmgen

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedJul 31, 2019
Enrollment StartJul 30, 2019
Primary CompletionNov 10, 2023
Study CompletionJan 31, 2024
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 6.9 years ago

Interventions

Tezepelumabbiological

Tezepelumab subcutaneous injection

Placeboother

Placebo subcutaneous injection